Regulated information

Q1 2019 sales: €90.9 million (up 3.7%)

Vetoquinol Group sales for Q1 2019 amounted to €90.9 million, up 2.3% at constant exchange rates and up 3.7% as reportedfrom the same period last year.

Vetoquinol finalizes acquisition of Clarion Biociencias in Brazil

Lure (France), April 16, 2019 - Vetoquinol today confirms the completion of its acquisition of Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.

Vetoquinol signs agreement to acquire Clarion Biociênciasin Brazil

On April 3rd, Vetoquinol signed an agreement to acquire Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.

Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%)

At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements.

2018 sales: up 3.2% to €367.9 million

9.1% GROWTH IN ESSENTIALS PRODUCTS AT CONSTANT EXCHANGE RATES

Vétoquinol continues to launch reference products

Lure (France), December 16, 2013 – In line with its strategy of developing products targeting fast-growing markets, the Vétoquinol Group expands its Flexadin® range world-wide and launches Zylkène® in the United States.

2013 3rd quarter sales show organic growth

Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates.

First half Results

2013 Half year results

Half year financial report 2013

2013 Half year Financial Report

The reference products demonstrate solid growth

Lure (France), August 29, 2013 – At its meeting on August 27, 2013, the Vétoquinol S.A. Board of Directors reviewed the Group’s results, and approved the financial statements for the first six months of 2013.